Global Dengue Treatment Market
Размер рынка в млрд долларов США
CAGR :
% 
 Прогнозируемый период |
2024 –2031 |
 Размер рынка (базовый год) |
USD 878.54 Million |
 Размер рынка (прогнозируемый год) |
USD 2,121.43 Million |
 CAGR |
% |
| Основные игроки рынка |
|
>Глобальный рынок лечения лихорадки денге по штаммам (DENV-2, DENV-3, DENV-1, DENV-4 и другие), типу (вакцины и ацетаминофен), тяжести (легкая и умеренная лихорадка денге и тяжелая лихорадка денге), способу введения (парентеральный и пероральный), способу приобретения (по рецепту и без рецепта (OTC)), полу (мужчине и женщине), возрасту (взрослому, ребенку и пожилому), конечному пользователю (больнице, специализированные клиники, домашняя медицинская помощь и другие), каналу сбыта (розничные аптеки, больничные аптеки и интернет-аптеки) — тенденции отрасли и прогноз до 2031 года.
Анализ и размер рынка лечения лихорадки денге
Факторами, обусловливающими рост мирового рынка лечения лихорадки денге, являются растущее применение лечения лихорадки денге в медицинской и фармацевтической промышленности, постоянное увеличение числа запусков вакцин, поскольку это расширяет арсенал инструментов, доступных медицинским работникам, и органы общественного здравоохранения. Однако существенным сдерживающим фактором для рынка являются побочные эффекты, связанные с лечением лихорадки денге.
По данным анализа Data Bridge Market Research, ожидается, что объем мирового рынка лечения лихорадки денге к 2031 году достигнет 2 121,43 млн долларов США по сравнению с 878,54 млн долларов США в 2023 году, а среднегодовой темп роста составит 11,6% в прогнозируемый период с 2024 по 2031 год.
|
Отчет Метрика |
Подробности |
|
Прогнозируемый период |
2024-2031 |
|
Базовый год |
2023 |
|
Исторические годы |
2022 (Можно настроить на 2016-2021) |
|
Количественные единицы |
Доход в млн. долл. США |
|
Охваченные сегменты |
Штаммы (DENV-2, DENV-3, DENV-1, DENV-4 и другие), тип ( вакцины и ацетаминофен), тяжесть (легкая или умеренная лихорадка денге и тяжелая лихорадка денге), способ введения (парентеральный и пероральный), способ приобретения (рецептурные и безрецептурные препараты), пол (мужской и женский), возраст (взрослый, детский и гериатрический), конечный пользователь (больница, специализированные клиники, домашняя медицинская помощь и другие), канал распространения (розничные аптеки, больничные аптеки и интернет-аптеки) |
|
Страна покрытия |
США, Канада, Мексика, Германия, Великобритания, Италия, Франция, Испания, Россия, Швейцария, Турция, Бельгия, Нидерланды, Остальная Европа, Япония, Китай, Южная Корея, Индия, Сингапур, Таиланд, Индонезия, Малайзия, Филиппины, Австралия, Остальная часть Азиатско-Тихоокеанского региона, Бразилия, Аргентина, Остальная часть Южной Америки, Южная Африка, Египет, Саудовская Аравия, ОАЭ, Израиль и Остальная часть Ближнего Востока и Африки |
|
Охваченные участники рынка |
Sanofi, Takeda Pharmaceutical Company Limited, Viatris Inc., Johnson & Johnson Services, Inc., GSK plc., Perrigo Company PLC, Baxter, Fresenius Kabi USA, Pfizer, Hikma Pharmaceuticals Plc, SUN PHARMACEUTICAL INDUSTRIES LTD, Teva Pharmaceuticals USA, Inc. и Aurobindo Pharma среди других |
Определение рынка
Dengue is a viral disease transmitted by mosquitoes which has spread rapidly in all WHO regions in recent years. The dengue virus is mainly transmitted by female mosquitoes from the genus Aedes aegypti and to a lesser degree, from Aedes albopictus. The diseases transmitted by these vector mosquitoes are Chikungunya, yellow fever and Zika viruses. Dengue is prevalent in the tropical geographic regions, induced by precipitation, temperature, relative humidity and unplanned rapid urbanization with local risk variability.
Global Dengue Treatment Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Dengue Incidence Rate Results in the Demand for Effective Treatment
The global increase in the incidence rate of dengue is a significant driver for the dengue treatment market. Dengue fever, caused by the dengue virus and transmitted by Aedes mosquitoes, has seen a dramatic rise in cases worldwide, particularly in tropical and subtropical regions. This surge is attributed to factors such as urbanization, climate change, and increased travel, which facilitate the spread of both the virus and its mosquito vectors. As the number of affected individuals grows, the demand for effective treatments and preventive measures intensifies. This has led to increased investment in research and development of antiviral drugs, vaccines, and supportive care options. Pharmaceutical companies and research institutions are intensifying their efforts to develop vaccines and innovative treatments to combat this pervasive disease. The high incidence rate, coupled with the potential for severe health complications and economic impact, is propelling investments and advancements in the dengue treatment market, aiming to mitigate the widespread and recurrent threat of dengue fever.
- Rising Wave of Dengue Vaccine Launches
The rise of dengue vaccine launches marks as an important factor in the fight against this mosquito-borne disease. With increasing awareness of the global burden of dengue and the pressing need for effective prevention strategies, pharmaceutical companies are stepping up their efforts to develop and introduce vaccines. This surge in vaccine launches serves as a significant driver for market growth, as it expands the arsenal of tools available to healthcare professionals and public health authorities. As more vaccines enter the market, competition intensifies, leading to innovation and improved formulations aimed at enhancing efficacy and safety. As a result, the dengue vaccine market is witnessing robust growth, with projections indicating sustained expansion in market share and revenue for key players in the years to come.
Opportunity
- Growing Number of Pipeline Vaccines for Dengue Treatment
The increasing number of pipeline vaccines for dengue treatment can enhance significant opportunities for market growth. With multiple candidates in development, there's potential for improved efficacy, safety, and coverage across diverse demographics and geographic regions. This aspect encourage healthy competition among developers, driving innovation and pushing for more cost-effective solutions. As dengue fever remains a global health concern, particularly in tropical and subtropical regions, the availability of more vaccines can help meet growing demand. The expanding pipeline of dengue vaccines not only addresses a critical public health need but also offers promising prospects for market growth through enhanced product offerings and increased opportunities for the pharmaceutical manufacturer.
Restraints/Challenges
- Healthcare Services are Limitedly Accessible in Rural Areas
Limited access to healthcare services in dengue treatment poses significant challenges for the market, primarily by reducing the patient pool and hindering timely diagnosis and treatment. With fewer patients seeking medical attention promptly, there's a risk of increased disease burden, leading to more severe cases and higher healthcare costs. Limited access exacerbates the strain on healthcare systems and resources in affected regions, potentially impacting the availability and affordability of dengue treatments. These rural regions lack well-equipped medical facilities and specialized services, making it difficult for residents to access timely and quality care. Rugged terrain and long distances to healthcare facilities exacerbate the problem, especially where transportation networks are inadequate. Overall, addressing barriers to healthcare access is crucial for effectively managing dengue and sustaining market growth in this sectorSafety concerns related to dengue treatment are a significant challenge, particularly given its widespread use in cosmetic and medical applications. While Dengue Treatment is generally considered safe and is naturally present in the human body, potential risks arise from its synthetic or extracted forms used in dermal fillers and other treatments. Adverse reactions can include allergic responses, infections, and granuloma formation, particularly if the substance is not properly purified or administered. Additionally, improper injection techniques can lead to complications such as vascular occlusion, which can cause tissue necrosis and, in severe cases, blindness. Ensuring the safety of Dengue Treatment products thus requires stringent quality control, thorough clinical testing, and professional administration by qualified healthcare providers.
- Delay in the Approval Process of Vaccines
Задержка в процессе одобрения вакцин от лихорадки денге представляет собой существенное ограничение для роста рынка, создавая многогранные проблемы как для разработчиков вакцин, так и для инициатив общественного здравоохранения. Нормативные барьеры, строгие требования к эффективности и безопасности и сложные протоколы испытаний способствуют увеличению сроков от разработки вакцины до ее доступности на рынке. Эти задержки препятствуют своевременному появлению вакцин, влияя на результаты общественного здравоохранения и увеличивая продолжительность вспышек заболеваний. Более того, длительные сроки одобрения могут сдерживать инвестиции в исследования и разработки вакцин, поскольку компании могут воспринимать более высокий риск неопределенности и снижения прибыльности. Кроме того, затянутый процесс одобрения подрывает доверие инвесторов, поскольку длительные циклы разработки увеличивают финансовые риски и неопределенность относительно окупаемости инвестиций. Более того, задержка доступности вакцин от лихорадки денге увековечивает зависимость от традиционных профилактических мер, таких как борьба с переносчиками и симптоматическое лечение, которые могут не обеспечивать комплексной защиты от заболевания. Это продлевает нагрузку на инфраструктуру здравоохранения, что приводит к увеличению расходов на здравоохранение и нагрузке на ресурсы в эндемичных регионах.
Последние события
- В мае 2024 года Johnson & Johnson (JNJ) объявила о своем окончательном соглашении о приобретении Yellow Jersey Therapeutics (YJT), дочерней компании Numab therapeutics, полностью принадлежащей ей, в рамках сделки за наличные на сумму около 1,25 млрд долларов США. Это стратегическое приобретение призвано укрепить траекторию роста JNJ за счет расширения ее портфеля в биофармацевтическом секторе. Интегрируя инновационный портфель и опыт YJT, JNJ стремится расширить свои возможности в разработке новых методов лечения, в конечном итоге укрепив свои позиции лидера в отрасли здравоохранения.
- В августе 2023 года, согласно статье FDA, DENGVAXIA, четырехвалентная живая вакцина, производимая Sanofi Pasteur, Inc., показана для профилактики лихорадки денге, вызываемой серотипами 1, 2, 3 и 4 вируса денге. Одобренная для лиц в возрасте от 6 до 16 лет, она специально предназначена для лиц, проживающих в эндемичных районах, у которых лабораторно подтверждена предыдущая инфекция денге. Эта вакцина представляет собой значительный прогресс в борьбе с лихорадкой денге, предлагая целевую защиту от нескольких серотипов вируса, тем самым потенциально снижая уровень заболеваемости инфекциями денге среди уязвимых групп населения.
- В феврале 2024 года, согласно статье Takeda Pharmaceutical Company Limited, компания взяла на себя обязательство производить до 50 миллионов доз в год QDENGA, вакцины против лихорадки Денге (живая, ослабленная), ускоряя достижение цели Takeda по поставке 100 миллионов доз в год к 2030 году. Эти флаконы для нескольких доз (MDV) предназначены для оказания помощи в государственных закупках для национальных программ иммунизации в эндемичных странах к 2030 году, способствуя более широкому доступу к вакцинации против лихорадки Денге и внося вклад в глобальные усилия по профилактике заболевания. Кроме того, две живые ослабленные вакцины против лихорадки Денге находятся на стадии разработки 3 фазы, а именно TDV, разработанная Takeda, и LAV Delta 30, разработанная NIH/Butantan Institute
- В июле 2019 года Hikma Pharmaceuticals Inc. и Civica Rx подписали долгосрочное соглашение, чтобы минимизировать будущий дефицит дженериков в регионе США. Это поможет компании расширить продажи дженериков и создать клиентскую базу, что увеличит чистую выручку и объем продаж.
- В ноябре 2019 года компания Perrigo Company plc объявила, что ее терапевтическая кампания «Quitting is Better» получила заметную национальную награду за лучшую кампанию корпоративной социальной ответственности безрецептурных препаратов. Компания победила в номинации «Инновации и стратегический маркетинг» по мнению жюри добровольцев, состоящего из представителей отрасли, являющихся членами Ассоциации производителей потребительских товаров для здоровья (CHPA). Это повысит узнаваемость компании в глобальном регионе
Мировой рынок лечения лихорадки денге Сфера применения
Глобальный рынок лечения лихорадки денге сегментирован на девять заметных сегментов, которые основаны на штаммах, типе, тяжести, пути введения, способе покупки, поле, возрасте, конечном пользователе и канале распространения. Рост среди сегментов помогает вам анализировать нишевые карманы роста и стратегии для выхода на рынок и определять ваши основные области применения и различия в ваших целевых рынках.
Штаммы
- ДЕНВ-2
- ДЕНВ-3
- ДЕНВ-1
- ДЕНВ-4
- Другие
На основе штаммов рынок сегментирован на DENV-2, DENV-3, DENV-1, DENV-4 и другие.
Тип
- Вакцина
- Ацетаминофен
По типу рынок сегментирован на вакцины и ацетаминофен.
Серьёзность
- Легкая и умеренная лихорадка денге
- Тяжелая лихорадка денге
По степени тяжести рынок подразделяется на легкую и умеренную лихорадку денге и тяжелую лихорадку денге.
Путь введения
- Парентеральный
- Оральный
По способу введения рынок сегментируется на парентеральный и пероральный.
Способ покупки
- Рецепт
- Безрецептурные (OTC)
По способу приобретения рынок сегментируется на рецептурные и безрецептурные препараты.
Пол
- Мужской
- Женский
По половому признаку рынок сегментируется на мужской и женский.
Возраст
- Взрослый
- Педиатрический
- гериатрический
По возрастному признаку рынок сегментируется на взрослый, детский и гериатрический.
Конечный пользователь
- Больница
- Специализированные клиники
- Домашнее здравоохранение
- Другие
По признаку конечного пользователя рынок сегментируется на больницы, специализированные клиники, учреждения здравоохранения на дому и другие.
Канал распространения
- Розничные аптеки
- Больничные аптеки
- Интернет-аптеки
По каналу сбыта рынок сегментируется на розничные аптеки, больничные аптеки и интернет-аптеки.
Региональный анализ/информация о мировом рынке лечения лихорадки денге
Проведен анализ мирового рынка средств для лечения лихорадки денге , а также предоставлены сведения о размерах рынка и тенденциях по штаммам, типу, степени тяжести, пути введения, способу приобретения, полу, возрасту, конечному пользователю и каналу сбыта.
Страны, охваченные мировым рынком лечения лихорадки денге : США, Канада, Мексика, Германия, Великобритания, Италия, Франция, Испания, Россия, Швейцария, Турция, Бельгия, Нидерланды, остальные страны Европы, Япония, Китай, Южная Корея, Индия, Сингапур, Таиланд, Индонезия, Малайзия, Филиппины, Австралия, остальные страны Азиатско-Тихоокеанского региона, Бразилия, Аргентина, остальные страны Южной Америки, Южная Африка, Египет, Саудовская Аравия, ОАЭ, Израиль, а также остальные страны Ближнего Востока и Африки.
Ожидается, что Азиатско-Тихоокеанский регион будет доминировать на мировом рынке лечения лихорадки денге из-за роста медицинского страхования в регионе. Ожидается, что Индия будет доминировать на рынке лечения лихорадки денге в Азиатско-Тихоокеанском регионе из-за растущей волны запусков вакцины от денге в стране. Ожидается, что Франция будет доминировать на рынке лечения лихорадки денге в Европе из-за правительственных инициатив и программ вакцинации в стране. Ожидается, что Бразилия будет доминировать на рынке лечения лихорадки денге в Южной Америке из-за роста заболеваемости денге в стране.
Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка, которые влияют на текущие и будущие тенденции рынка. Такие данные, как анализ цепочки создания стоимости вверх и вниз по течению, технические тенденции и анализ пяти сил Портера, тематические исследования — вот некоторые из указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам учитываются наличие и доступность глобальных брендов и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, влияние внутренних тарифов и торговых путей.
Анализ конкурентной среды и доли мирового рынка лечения лихорадки денге
Глобальная конкурентная среда лечения лихорадки денге содержит данные по конкурентам. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в НИОКР, новых рыночных инициативах, сильных и слабых сторонах компании, запуске продукта, одобрении продукта, доминировании приложений и жизненно важной кривой типа продукта. Приведенные выше данные касаются только фокуса компании на рынке.
Среди основных игроков, работающих на этом рынке, можно назвать Sanofi, Takeda Pharmaceutical Company Limited, Viatris Inc., Johnson & Johnson Services, Inc., GSK plc., Perrigo Company PLC, Baxter, Fresenius Kabi USA, Pfizer, Hikma Pharmaceuticals Plc, SUN PHARMACEUTICAL INDUSTRIES LTD, Teva Pharmaceuticals USA, Inc. и Aurobindo Pharma и другие.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL DENGUE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 GLOBAL DENGUE TREATMENT MARKET: REGULATIONS
5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT
6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES
6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
6.2 RESTRAINTS
6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES
6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE
6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE
6.3 OPPORTUNITIES
6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET
6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT
6.3.3 RISING R&D INVESTMENT AND ACTIVITIES
6.4 CHALLENGES
6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS
6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS
7 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS
7.1 OVERVIEW
7.2 DENV-2
7.3 DENV-3
7.4 DENV-1
7.5 DENV-4
7.6 OTHERS
8 GLOBAL DENGUE TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 VACCINES
8.2.1 DENGVAXIA (CYD-TDV)
8.2.2 QDENGA
8.3 ACETAMINOPHEN
8.3.1 PARENTERAL
8.3.2 ORAL
8.3.3 OTHER
9 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY
9.1 OVERVIEW
9.2 MILD TO MODERATE DENGUE
9.3 SEVERE DENGUE
10 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 PARENTERAL
10.2.1 SUB-CUTANEOUS
10.2.2 INTRAVENOUS
10.3 ORAL
10.3.1 TABLET
10.3.2 CAPSULES
10.3.3 OTHERS
11 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE
11.1 OVERVIEW
11.2 PRESCRIPTION
11.3 OVER-THE-COUNTER (OTC)
12 GLOBAL DENGUE TREATMENT MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 GLOBAL DENGUE TREATMENT MARKET, BY AGE
13.1 OVERVIEW
13.2 ADULT
13.3 PEDIATRIC
13.4 GERIATRIC
14 GLOBAL DENGUE TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL PHARMACIES
15.3 HOSPITAL PHARMACIES
15.4 ONLINE PHARMACIES
16 GLOBAL DENGUE TREATMENT MARKET, BY REGION
16.1 OVERVIEW
16.2 ASIA-PACIFIC
16.2.1 INDIA
16.2.2 CHINA
16.2.3 JAPAN
16.2.4 INDONESIA
16.2.5 MALAYSIA
16.2.6 THAILAND
16.2.7 AUSTRALIA
16.2.8 SOUTH KOREA
16.2.9 SINGAPORE
16.2.10 PHILIPPINES
16.2.11 REST OF ASIA-PACIFIC
16.3 SOUTH AMERICA
16.3.1 BRAZIL
16.3.2 ARGENTINA
16.3.3 REST OF SOUTH AMERICA
16.4 NORTH AMERICA
16.4.1 MEXICO
16.4.2 U.S.
16.4.3 CANADA
16.5 EUROPE
16.5.1 FRANCE
16.5.2 GERMANY
16.5.3 SPAIN
16.5.4 U.K.
16.5.5 BELGIUM
16.5.6 ITALY
16.5.7 NETHERLANDS
16.5.8 RUSSIA
16.5.9 SWITZERLAND
16.5.10 TURKEY
16.5.11 REST OF EUROPE
16.6 MIDDLE EAST AND AFRICA
16.6.1 EGYPT
16.6.2 SAUDI ARABIA
16.6.3 SOUTH AFRICA
16.6.4 U.A.E
16.6.5 ISRAEL
16.6.6 REST OF MIDDLE EAST AND AFRICA
17 GLOBAL DENGUE TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 SANOFI
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 JOHNSON & JOHNSON SERVICES, INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 GSK PLC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 AUROBINDO PHARMA
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.7 BAXTER
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.8 FRESENIUS KABI USA
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 HIKMA PHARMACEUTICALS
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 PERRIGO COMPANY PLC
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 PFIZER INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 TEVA PHARMACEUTICALS USA, INC.
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Список таблиц
TABLE 1 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 2 IMPACT OF DELAY IN APPROVAL PROCESS
TABLE 3 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 4 GLOBAL DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 GLOBAL DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 13 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 14 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 17 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 18 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 19 GLOBAL MILD TO MODERATE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 GLOBAL SEVERE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 22 GLOBAL PARENTERAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 GLOBAL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 GLOBAL ORAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 GLOBAL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 27 GLOBAL PRESCRIPTION IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 28 GLOBAL OVER-THE-COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 GLOBAL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 30 GLOBAL MALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 GLOBAL FEMALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 GLOBAL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 33 GLOBAL ADULT IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 GLOBAL PEDIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 35 GLOBAL GERIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 GLOBAL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 37 GLOBAL HOSPITAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 GLOBAL SPECIALITY CLINICS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 39 GLOBAL HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 GLOBAL OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 GLOBAL RETAIL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 GLOBAL HOSPITAL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 GLOBAL ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 GLOBAL DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 46 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 47 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 48 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 50 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 51 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 52 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 54 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 55 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 56 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 57 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 60 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 61 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 62 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 63 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 64 INDIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 65 INDIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 68 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 69 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 71 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 72 INDIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 73 INDIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 74 INDIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 INDIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 INDIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 77 INDIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 78 INDIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 79 INDIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 80 INDIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 81 CHINA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 82 CHINA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 85 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 86 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 88 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 89 CHINA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 90 CHINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 91 CHINA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 CHINA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 CHINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 94 CHINA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 95 CHINA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 96 CHINA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 97 CHINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 98 JAPAN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 99 JAPAN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 102 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 103 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 105 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 106 JAPAN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 107 JAPAN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 108 JAPAN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 JAPAN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 JAPAN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 111 JAPAN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 112 JAPAN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 113 JAPAN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 114 JAPAN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 115 INDONESIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 116 INDONESIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 117 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 118 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 119 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 120 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 121 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 122 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 123 INDONESIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 124 INDONESIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 125 INDONESIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 INDONESIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 INDONESIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 128 INDONESIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 129 INDONESIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 130 INDONESIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 131 INDONESIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 132 MALAYSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 133 MALAYSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 135 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 136 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 137 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 139 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 140 MALAYSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 141 MALAYSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 142 MALAYSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 MALAYSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 MALAYSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 145 MALAYSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 146 MALAYSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 147 MALAYSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 148 MALAYSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 149 THAILAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 150 THAILAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 151 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 152 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 153 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 154 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 156 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 157 THAILAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 158 THAILAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 159 THAILAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 THAILAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 THAILAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 162 THAILAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 163 THAILAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 164 THAILAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 165 THAILAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 166 AUSTRALIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 167 AUSTRALIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 170 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 171 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 173 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 174 AUSTRALIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 175 AUSTRALIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 176 AUSTRALIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 177 AUSTRALIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 AUSTRALIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 179 AUSTRALIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 180 AUSTRALIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 181 AUSTRALIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 182 AUSTRALIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 183 SOUTH KOREA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 184 SOUTH KOREA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 187 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 188 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 190 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 191 SOUTH KOREA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 192 SOUTH KOREA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 193 SOUTH KOREA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 SOUTH KOREA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 195 SOUTH KOREA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 196 SOUTH KOREA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 197 SOUTH KOREA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 198 SOUTH KOREA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 199 SOUTH KOREA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 200 SINGAPORE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 201 SINGAPORE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 204 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 205 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 207 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 208 SINGAPORE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 209 SINGAPORE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 210 SINGAPORE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 211 SINGAPORE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 212 SINGAPORE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 213 SINGAPORE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 214 SINGAPORE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 215 SINGAPORE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 216 SINGAPORE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 217 PHILIPPINES DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 218 PHILIPPINES DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 220 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 221 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 222 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 224 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 225 PHILIPPINES DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 226 PHILIPPINES DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 227 PHILIPPINES PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 PHILIPPINES ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 PHILIPPINES DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 230 PHILIPPINES DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 231 PHILIPPINES DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 232 PHILIPPINES DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 233 PHILIPPINES DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 234 REST OF ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 235 SOUTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 236 SOUTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 237 SOUTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 239 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 240 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 241 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 242 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 243 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 244 SOUTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 245 SOUTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 246 SOUTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 247 SOUTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 SOUTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 249 SOUTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 250 SOUTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 251 SOUTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 252 SOUTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 253 BRAZIL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 254 BRAZIL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 257 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 258 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 260 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 261 BRAZIL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 262 BRAZIL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 263 BRAZIL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 264 BRAZIL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 265 BRAZIL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 266 BRAZIL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 267 BRAZIL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 268 BRAZIL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 BRAZIL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 270 ARGENTINA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 271 ARGENTINA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 272 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 274 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 275 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 276 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 277 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 278 ARGENTINA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 279 ARGENTINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 280 ARGENTINA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 ARGENTINA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 282 ARGENTINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 283 ARGENTINA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 284 ARGENTINA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 285 ARGENTINA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 286 ARGENTINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 287 REST OF SOUTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 288 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 289 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 290 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 292 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 293 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 294 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 295 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 296 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 297 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 298 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 299 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 300 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 301 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 302 NORTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 303 NORTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 304 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 305 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 306 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 307 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 308 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 309 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 310 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 311 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 312 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 313 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 314 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 315 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 316 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 317 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 318 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 319 MEXICO DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 320 MEXICO DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 321 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 322 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 323 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 324 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 325 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 326 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 327 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 328 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 329 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 330 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 331 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 332 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 333 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 334 U.S. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 335 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 336 U.S. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 337 U.S. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 338 U.S. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 339 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 340 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 341 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 342 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 343 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 344 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 345 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 346 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 347 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 348 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 349 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 350 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 351 CANADA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 352 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 353 CANADA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 354 CANADA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 355 CANADA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 356 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 357 EUROPE DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 358 EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 359 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 360 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 361 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 362 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 363 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 364 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 365 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 366 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 367 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 368 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 369 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 370 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 371 EUROPE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 372 EUROPE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 373 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 374 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 375 FRANCE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 376 FRANCE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 377 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 378 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 379 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 380 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 381 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 382 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 383 FRANCE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 384 FRANCE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 385 FRANCE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 386 FRANCE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 387 FRANCE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 388 FRANCE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 389 FRANCE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 390 FRANCE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 391 FRANCE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 392 GERMANY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 393 GERMANY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 394 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 395 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 396 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 397 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 398 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 399 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 400 GERMANY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 401 GERMANY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 402 GERMANY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 403 GERMANY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 404 GERMANY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 405 GERMANY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 406 GERMANY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 407 GERMANY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 408 GERMANY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 409 SPAIN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 410 SPAIN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 411 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 412 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 413 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 414 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 415 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 416 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 417 SPAIN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 418 SPAIN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 419 SPAIN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 420 SPAIN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 421 SPAIN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 422 SPAIN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 423 SPAIN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 424 SPAIN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 425 SPAIN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 426 U.K. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 427 U.K. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 428 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 429 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 430 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 431 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 432 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 433 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 434 U.K. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 435 U.K. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 436 U.K. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 437 U.K. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 438 U.K. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 439 U.K. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 440 U.K. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 441 U.K. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 442 U.K. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 443 BELGIUM DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 444 BELGIUM DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 445 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 446 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 447 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 448 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 449 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 450 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 451 BELGIUM DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 452 BELGIUM DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 453 BELGIUM PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 454 BELGIUM ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 455 BELGIUM DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 456 BELGIUM DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 457 BELGIUM DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 458 BELGIUM DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 459 BELGIUM DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 460 ITALY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 461 ITALY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 462 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 463 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 464 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 465 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 466 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 467 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 468 ITALY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 469 ITALY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 470 ITALY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 471 ITALY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 472 ITALY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 473 ITALY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 474 ITALY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 475 ITALY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 476 ITALY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 477 NETHERLANDS DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 478 NETHERLANDS DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 479 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 480 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 481 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 482 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 483 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 484 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 485 NETHERLANDS DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 486 NETHERLANDS DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 487 NETHERLANDS PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 488 NETHERLANDS ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 489 NETHERLANDS DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 490 NETHERLANDS DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 491 NETHERLANDS DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 492 NETHERLANDS DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 493 NETHERLANDS DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 494 RUSSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 495 RUSSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 496 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 497 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 498 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 499 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 500 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 501 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 502 RUSSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 503 RUSSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 504 RUSSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 505 RUSSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 506 RUSSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 507 RUSSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 508 RUSSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 509 RUSSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 510 RUSSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 511 SWITZERLAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 512 SWITZERLAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 513 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 514 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 515 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 516 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 517 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 518 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 519 SWITZERLAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 520 SWITZERLAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 521 SWITZERLAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 522 SWITZERLAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 523 SWITZERLAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 524 SWITZERLAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 525 SWITZERLAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 526 SWITZERLAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 527 SWITZERLAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 528 TURKEY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 529 TURKEY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 530 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 531 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 532 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 533 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 534 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 535 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 536 TURKEY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 537 TURKEY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 538 TURKEY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 539 TURKEY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 540 TURKEY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 541 TURKEY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 542 TURKEY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 543 TURKEY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 544 TURKEY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 545 REST OF EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 546 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 547 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 548 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 549 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 550 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 551 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 552 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 553 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 554 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 555 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 556 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 557 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 558 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 559 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 560 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 561 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 562 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 563 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 564 EGYPT DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 565 EGYPT DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 566 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 567 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 568 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 569 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 570 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 571 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 572 EGYPT DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 573 EGYPT DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 574 EGYPT PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 575 EGYPT ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 576 EGYPT DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 577 EGYPT DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 578 EGYPT DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 579 EGYPT DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 580 EGYPT DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 581 SAUDI ARABIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 582 SAUDI ARABIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 583 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 584 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 585 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 586 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 587 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 588 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 589 SAUDI ARABIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 590 SAUDI ARABIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 591 SAUDI ARABIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 592 SAUDI ARABIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 593 SAUDI ARABIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 594 SAUDI ARABIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 595 SAUDI ARABIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 596 SAUDI ARABIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 597 SAUDI ARABIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 598 SOUTH AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 599 SOUTH AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 600 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 601 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 602 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 603 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 604 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 605 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 606 SOUTH AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 607 SOUTH AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 608 SOUTH AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 609 SOUTH AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 610 SOUTH AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 611 SOUTH AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 612 SOUTH AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 613 SOUTH AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 614 SOUTH AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 615 U.A.E DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 616 U.A.E DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 617 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 618 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 619 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 620 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 621 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 622 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 623 U.A.E DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 624 U.A.E DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 625 U.A.E PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 626 U.A.E ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 627 U.A.E DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 628 U.A.E DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 629 U.A.E DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 630 U.A.E DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 631 U.A.E DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 632 ISRAEL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 633 ISRAEL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 634 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 635 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 636 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 637 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 638 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 639 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 640 ISRAEL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 641 ISRAEL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 642 ISRAEL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 643 ISRAEL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 644 ISRAEL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 645 ISRAEL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 646 ISRAEL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 647 ISRAEL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 648 ISRAEL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 649 REST OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
Список рисунков
FIGURE 1 GLOBAL DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL DENGUE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL DENGUE TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL DENGUE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 11 GROWING PHARMACEUTICAL INDUSTRY IS DRIVING THE GROWTH OF THE GLOBAL DENGUE TREATMENT MARKET FROM 2024 TO 2031
FIGURE 12 ON THE BASIS OF STRAINS, THE DENV-2 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DENGUE TREATMENT MARKET IN 2024 AND 2031
FIGURE 13 ASIA-PACIFIC IS EXPECTED TO DOMINATE THE GLOBAL DENGUE TREATMENT MARKET AND EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR GLOBAL DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL DENGUE TREATMENT MARKET
FIGURE 16 FINANCIAL BUDGET FOR VECTOR-BORNE -DISEASES INCLUDING DENGUE IN INDIA
FIGURE 17 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, 2023
FIGURE 18 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, 2024-2031 (USD MILLION)
FIGURE 19 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2024-2031)
FIGURE 20 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 21 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, 2023
FIGURE 22 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 23 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 24 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, 2023
FIGURE 26 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, 2024-2031 (USD MILLION)
FIGURE 27 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2024-2031)
FIGURE 28 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 29 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 30 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 31 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 32 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 33 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2023
FIGURE 34 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
FIGURE 35 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)
FIGURE 36 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 37 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, 2023
FIGURE 38 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)
FIGURE 39 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 40 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 41 GLOBAL DENGUE TREATMENT MARKET: BY AGE, 2023
FIGURE 42 GLOBAL DENGUE TREATMENT MARKET: BY AGE, 2024-2031 (USD MILLION)
FIGURE 43 GLOBAL DENGUE TREATMENT MARKET: BY AGE, CAGR (2024-2031)
FIGURE 44 GLOBAL DENGUE TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 45 GLOBAL DENGUE TREATMENT MARKET: BY END USER, 2023
FIGURE 46 GLOBAL DENGUE TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 47 GLOBAL DENGUE TREATMENT MARKET: BY END USER, CAGR (2024-2031)
FIGURE 48 GLOBAL DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 49 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 50 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 51 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 52 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 GLOBAL DENGUE TREATMENT MARKET: SNAPSHOT (2023)
FIGURE 54 GLOBAL DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 55 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 56 EUROPE DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 57 AISA-PACIFIC DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
